MAJOR perioperative cardiac events in patients undergoing noncardiac surgery continue to be a significant source of perioperative morbidity with ranges from 1.4% in relatively unselected patients1
to 6% in patients older than 70 yr with cardiac disease.2
Moreover, perioperative myocardial infarction (PMI) is one of the most important predictors of short- and long-term morbidity and mortality associated with noncardiac surgery.3–6
The actual rate of PMI varies between studies in part because of the definition used and the method of surveillance. Part of the definition depends on the biomarkers (e.g.
, creatine kinase [CK], lactate dehydrogenase, and troponin) used to define PMI. This article will review the evolution in the use of biomarkers and how more specific biomarkers have increased the rate of PMI detected.7
Definition of PMI
According to the traditional definition, at least two of the three criteria must be fulfilled to diagnose myocardial infarction (MI): (i) typical ischemic chest pain; (ii) increased serum concentration of CK-MB (myocardial band) isoenzyme; and (iii) typical electrocardiographic findings, including development of pathologic Q waves. The advent of sensitive and specific serologic biomarkers has resulted in a major shift in the classic paradigms for diagnosing infarction.
Devereaux et al.8
suggest that only 14% of patients experiencing a PMI will have chest pain and only 53% will have a clinical sign or symptom that may trigger a physician to consider an MI. The large proportion of clinically unrecognized MIs can be explained by several factors present in the immediate postoperative period: analgesics, intubation and sedation, and a host of more common explanations for potential signs and symptoms, such as atelectasis, pneumonia, hypovolemia, and bleeding.
Electrocardiography plays a key role in the diagnostic workup of suspected MI. The changes in the ST-T waveforms and the Q waves potentially allow the clinician to date the event, to suggest the infarct-related artery, and to estimate the amount of myocardium at risk. Electrocardiography criteria for diagnosis of acute MI in the absence of left ventricular hypertrophy and left bundle branch block are ST elevation MI—new ST elevation at the J-point in two contiguous leads with the cutoff points: more than or equal to 0.2 mV in men or more than or equal to 0.15 mV in women in leads V2–V3 and/or more than or equal to 0.1 mV in other leads; non-ST elevation MI (ST depression and T-wave changes)—new horizontal or down-sloping ST depression more than or equal to 0.05 mV in two contiguous leads; and/or T inversion more than or equal to 0.1 mV in two contiguous leads with prominent R wave or R/S ratio more than 1.
However, the electrocardiogram by itself is often insufficient to diagnose acute myocardial ischemia or infarction because ST deviation may be observed in other conditions such as acute pericarditis, left ventricular hypertrophy, left bundle branch block, Brugada syndrome, and early repolarization patterns. Furthermore, in cardiomyopathy, for example, Q waves may occur due to myocardial fibrosis.9
A more complete review can be found elsewhere.10
Biochemical Markers—Evolution of the Tests Used for Biochemical Detection of Heart Damage
Measurement of cardiac markers in blood has been the mainstay for diagnosis of acute MI for nearly 50 yr.
A loss of cellular integrity of the sarcolemma results in the release of a number of proteins into the circulation that can be used as biochemical markers of acute myocardial necrosis. CK, SGOT (more recently known as AST), lactate dehydrogenase, myoglobin, and troponins are some of these markers. The timing of their appearance and disappearance in blood is mainly dependent on quantity of release, molecular size, and solubility (fig. 1
). The first practical test used for biochemical detection of myocardial damage was the measurement of transaminases described in 1954.11
Having wide tissue distribution, AST and lactate dehydrogenase are less specific for myocardial necrosis and offer no advantage over CK isoenzymes. Myoglobin, a heme-related protein abundant in cardiac and skeletal muscle, is an early marker of myocardial necrosis. It is detectable in the plasma 1–2 h after the onset of chest pain, with a peak at 3–8 h. With the availability of assays for CK isoenzymes, these tests were gradually abandoned, at least for an early diagnosis of MI.
CK is the enzyme responsible for catalyzing the transfer of high-energy phosphate from creatine phosphate to adenosine triphosphate. CK is known to rise within 4–8 h after an acute MI and to decline to normal levels within 3–4 days. In 1960, Dreyfus et al.12
demonstrated markedly increased plasma CK activity in patients with MI. Total CK found in the normal circulation varies tremendously, and CK is a well-recognized marker of rhabdomyolysis. The problem of multiple etiologies makes interpretation of CK release more difficult in the surgical population.
In 1966, van der Veen and Willebrands13
demonstrated that CK-MB is a highly specific marker of MI. In the 1970s, it became evident that CK-MB was to be the standard for the diagnostic and quantitative assessment of MI. CK isoenzyme analysis substantially increased the sensitivity of this test for the diagnosis of acute MI. However, other types of myocardial injury, such as myocarditis, trauma, and cardiac surgery, also cause the release of CK-MB.14
A variety of techniques were developed to further improve the sensitivity and rapidity of assaying for CK-MB. In the mid-1980s, the development of an antibody specific for CK-MB15
marked the beginning of the era of immunologic detection of biomarkers. This technique of mass assay offered the advantage of measuring protein concentration over enzymatic activity. With direct analysis of CK-MB irrespective of total activity, it was quickly recognized that the myocardium is not the only tissue containing large amounts of CK-MB as initially believed.16
CK-MB has been found in the small intestine, tongue, diaphragm, uterus, and prostate. Skeletal muscles also contain CK-MB in small amounts. In the surgical setting, the use of the CK-MB fraction is complicated by increased levels of both total CK and noncardiac CK-MB.
The shift from transaminases and dehydrogenases to isoenzymes of the latter and then to CK, CK-MB, and CK-MB mass improved test precision, resulting in greater sensitivity and specificity in the diagnosis of MI over time and better case classifications. However, these tests still did not allow the definite distinction of skeletal and cardiac muscle injuries. This lack of cardiospecificity accelerated the desire for a more specific test than CK-MB.
CK-MB was considered the benchmark for MI diagnosis from the 1980s through the late 1990s. The diagnostic sensitivity of both CK-MB (activity or mass) and the troponins markedly increases with time. Sampling to at least 10 h yields approximately 90% diagnostic sensitivity with either biomarker.17
In a meta-analysis by Balk et al.
CK-MB showed a rather low cumulative sensitivity of 79% and a cumulative specificity of 96% in emergency department patients. It could be argued, however, that inclusion of studies that mixed results of assays, different cutoff strategies, and less than ideal sampling almost certainly led to underestimation of diagnostic sensitivity. Wu and Lane19
limited inclusion to studies that used CK-MB mass assays in samples collected over the appropriate timeframe of 12–24 h after the onset of symptoms. Their meta-analysis reported a cumulative sensitivity of 97% and cumulative specificity of 90%.
The cardiac troponins are regulatory proteins with both cytosolic and structural pools that are released because of necrosis. The troponin complex is located on the thin filament of striated muscle and consists of three subunits: troponin T, a binding protein that attaches the troponin complex to tropomyosin; troponin I, which modulates the interaction of actin and myosin by acting as an inhibitor of actomyosin adenosine triphosphatase activity; and troponin C, the calcium-binding subunit of the troponin complex. The cardiac forms are designated cardiac troponin I (cTnI) and cardiac troponin T (cTnT). Cardiac troponin has nearly absolute myocardial tissue specificity and high clinical sensitivity.20
Several large studies of patients with acute coronary syndrome support the clinical efficacy of troponin over the previous gold standard: the CK and its MB fraction.
Although there is only one assay for cTnT, there is a multiplicity of assays for cTnI with substantial heterogeneity of assay sensitivities.21
Manufacturers are now developing a new generation of high-sensitivity cTn assays that are more precise at low concentrations and measure cTn concentration at less than 1 ng/l. Of note, cTn assays are neither standardized nor harmonized. Different assays are composed of different antibody configurations recognizing different epitopes of cTnI, suggesting that specific assays may detect slightly different groups of patients, depending on the nature and timing of cTn release.22
The performance of assays and the release kinetics and plasma clearance of both troponin T and I have been described elsewhere.23–25
An increased value for cardiac troponin is defined as a measurement exceeding the 99th percentile of a normal reference population (upper reference limit). Detection of a rise and/or fall of troponin is essential to the diagnosis of acute MI. Blood samples for measurement of troponin should be drawn on first assessment and 6–9 h later. The above-mentioned discriminatory percentile is designated as the decision level for the diagnosis of MI and must be determined for each specific assay with appropriate quality control. It has also been recommended that optimal test reproducibility should be defined as less than or equal to 10% imprecision at the 99th percentile upper reference limit for each assay.
One of the biggest issues apart from the problem of selecting relevant reference subjects is the current practice of the Food and Drug Administration of approving assays based on higher receiver-operating characteristic-optimized cutoffs. In a recent issue of clinical chemistry, Apple26
introduced his concept of a scorecard approach to decide which assays are acceptable for use in clinical practice. He proposed a two-tier system using both the 99th percentiles and imprecision values at the 99th percentile based on a young, healthy reference population that is diversified by sex, race, and ethnicity.
Studies Evaluating the Role of the Troponins for Diagnosis of PMI
The first major study to evaluate the perioperative use of cTnI was conducted by Adams et al.27
The authors compared electrocardiogram, total CK, CK-MB, and cTnI with the gold standard (new akinesia or dyskinesia on postoperative transthoracic echocardiography) for detection of perioperative infarction in 108 patients undergoing vascular or spine surgery. Blood samples were obtained every 6 h for a least the first 36 h after surgery. In this population, a PMI as defined by new abnormalities of wall motion was diagnosed in 8 patients (8%). The sensitivity of cTnI was 100% and that of CK-MB was 75%. The difference between the specificity of cTnI (99%) and that of CK-MB (81%) was significant (P
< 0.005). Thus, these data did not establish the superior sensitivity of cTnI compared with CK-MB, only its superior specificity for the detection of perioperative infarction.
Lee et al.28
evaluated the diagnostic performance of cTnT as a marker for myocardial injury in 1,175 patients aged 50 yr or older and undergoing major noncardiac surgery. CK-MB and electrocardiographic criteria were used to define acute MI. cTnT was measured in the recovery room after surgery and on the next two postoperative mornings. Acute MI was diagnosed in 17 patients (1.4%). cTnT increases occurred in 87% of patients with MI and in 16% of patients without MI, yielding a sensitivity of 87% and a specificity of 84%. The receiver-operating characteristic curves indicated that the two tests had similar diagnostic performance in detecting MI but that cTnT was superior for prediction of complications.
Metzler et al.29
conducted a study with the aim of examining the perioperative pattern of changes in troponin. Blood sampling was performed daily from the day before surgery until the fifth postoperative day (POD) in 67 patients with cardiac risk undergoing elective noncardiac surgery. Eight of the 13 patients (12%) with increased cTnT concentrations had an adverse outcome. In seven patients, CK-MB and troponin increases were discordant. With a cTnT cutoff at 0.2 ng/ml, the positive and negative predictive values for adverse outcome were only 62% and 100%, respectively. By choosing a higher cutoff of 0.6 ng/ml, the positive and negative predictive values for adverse outcome were 88% and 98%.
Haggart et al.30
compared the value of cTnI and CK/CK-MB ratios for detection of myocardial injury in 59 patients undergoing either emergency (24) or elective aortic surgery. More than half the patients undergoing emergency surgery and more than a quarter of those having elective surgery suffered myocardial necrosis as determined by detectable cTnI levels. This was accompanied by an increased CK-MB/CK ratio in less than one-fifth of patients.
The use of cTnI in diagnosing PMI in the setting of orthopedic surgery was evaluated by Jules-Elysee et al.31
in 85 patients with risk factors for coronary artery disease. In this population, cTnI seemed to be as sensitive as and more specific than the CK-MB index.
Martinez et al.32
evaluated surveillance strategies for the diagnosis of PMI using TnI in a cohort of 467 patients at high risk who required noncardiac surgery, with the goal of identifying the highest diagnostic yield. The diagnosis of myocardial injury was determined by biomarkers combined with either postoperative changes on 12-lead electrocardiogram or one of three clinical symptoms consistent with MI (chest pain, dyspnea, or requirement for hemodynamic support). The incidence of MI was 9.0% by the criterion of cTnI greater than or equal to 2.6 ng/ml, 19% by TnI greater than or equal to 1.5 ng/ml, 13% by CK-MB mass, and 2.8% by CK-MB ratio. The specificity of TnI greater than or equal to 2.6 ng/ml as an indicator of MI was 98%, and its positive predictive value was 85%. Using this cutoff, the strategy with the highest diagnostic yield was surveillance on PODs 1, 2, and 3.
Le Manach et al.33
used cTnI surveillance after abdominal aortic surgery in 1,136 patients to better evaluate the incidence and timing of PMI (TnI ≥ 1.5 ng/ml) or myocardial damage (abnormal cTnI < 1.5 ng/ml). Abnormal cTnI concentrations were noted in 163 patients (14%), of whom 106 (9%) had myocardial damage and 57 (5%) had PMI. In 34 patients (3%), PMI was preceded by a prolonged (>24 h) period of increased cTnI, and in 21 patients (2%) the increase in cTnI lasted less than 24 h. Abnormal but low postoperative cTnI was associated with increased mortality and could lead to MI. The authors concluded that they had identified two different types of PMI, early and delayed (fig. 2
Studies Evaluating the Role of the Troponins for Both Diagnosis and Prognosis
The fact that, in the cohort studied by Lee et al.
90% of patients with cTnT increases did not have clinical complications during the perioperative follow-up raised the question whether these values were false-positive results or evidence of subclinical myocardial injury. To address this issue, Lopez-Jimenez et al.34
collected 6-month follow-up data on a subcohort of 772 patients from the previous study. During the follow-up period, there were 19 (2.5%) major cardiac complications. A cTnT value more than 0.1 ng/ml was an independent correlate of cardiac events, whereas CK-MB was not correlated with postdischarge cardiac events.
Badner et al.35
intensively monitored isoenzyme and electric activity of the heart for the first 7 postoperative days in 323 patients with ischemic heart disease, aged 50 yr or older, and undergoing noncardiac surgery. After surgery, patients had daily clinical assessments, electrocardiograms, and measurements of CK, CK-MB, and cTnT (not used in the first 92 patients) on the operative night, twice daily on PODs 1–4, and then daily on days 5–7. The criteria for PMI diagnosis were designed to require the presence of an indicator of high sensitivity (increased total CK) and at least two indicators of high specificity (increased CK-MB, increased cTnT, Q waves, or a positive result of a pyrophosphate scan). The authors observed a 6% incidence for PMI using these criteria. With 14 of 18 events occurring during the first postoperative night, they corroborated the finding that PMI is an early postoperative event in patients with known ischemic heart disease. Use of TnT increase as a sole criterion for the diagnosis of PMI would have nearly doubled the incidence and moved the peak of event occurrence to the first POD. Interestingly, 1-year follow-up suggested that patients with silent PMIs have similar short-term outcomes as those with symptomatic PMIs.
Neill et al.36
evaluated the changes in cardiac protein concentrations (CK-MB, cTnT, and cTnI) after vascular or major orthopedic surgery in 80 patients older than 45 yr. The authors compared these changes as markers of postoperative cardiac complications with the incidence of ambulatory electrocardiographic changes for silent myocardial ischemia. Eight patients (10%) had major and 21 patients (27%) had minor postoperative complications. Both cTnT and cTnI showed high specificity for major complications, 96% and 97% respectively, but sensitivity was only 43% for cTnT and 29% for cTnI. There were no associations between postoperative ischemia and cardiac protein concentrations. At 3-month follow-up, cTnT correlated best with complications.
The ideal discrimination value of cTnI between the “complicated and uncomplicated” patient groups was investigated by Godet et al.37
in 329 patients undergoing infrarenal aortic surgery. cTnI was measured at recovery and on PODs 1–3. MI was defined as new Q wave or prolonged ST-T depression for more than 2 days. Thirteen patients (4%) developed 19 relevant cardiac complications (cardiac failure, MI, and cardiac death) in the postoperative period. A cTnI level greater than 0.54 ng/ml was correlated with the occurrence of postoperative cardiac complications in the period until discharge. That cutoff yielded a sensitivity of 75% and a specificity of 89%. Late cardiac complications occurring in the first year after aortic surgery were not correlated with cTnI.
Kim et al.38
found that increased cTnI levels were associated with a significantly increased risk of PMI and 6-month mortality in a group of 229 patients after major vascular surgery. They further reported a dose–response relation between cTnI concentration and mortality.
Transition to the Use of Troponin
According to the new universal definition of MI, any of the following criteria meets the diagnosis for MI: detection of rise or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia; electrocardiogram changes indicative of new ischemia (new ST-T changes or new left bundle branch block); development of pathologic Q waves in the electrocardiogram; and imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.39
However, it is important to keep in mind that nearly all the well-accepted studies of clinical risk stratification are based at least in part on diagnosis of PMI using adaptations of the World Health Organization definition, which requires any two of three criteria: ischemic symptoms, electrocardiographic changes, and increased CK-MB levels.
In summary, the available studies highlight the difficulty of using cardiac-specific troponin to distinguish myocardial damage from infarction. Commonly, troponin increase alone is mistakenly equated with the diagnosis of MI. However, many conditions may be associated with increased troponin levels, including neurologic injury, brain death, hemorrhagic shock, cardiac trauma, sepsis, hypotension, renal insufficiency, pulmonary embolism, heart failure, and any other condition with increased ventricular wall stress.40–44
Furthermore, although recently any increase in troponin in the appropriate clinical setting had been considered indicative of myocardial necrosis rather than ischemia, results from the Protein Markers of Ischemia using Proteomic Testing—TIMI 35 study showed that transient stress-induced myocardial ischemia is associated with a quantifiable increase in circulating troponin that is detectable with a novel, ultrasensitive cTnI assay.45
Another issue that remains to be addressed is use in terms of guiding aggressiveness of care. Even if we believe that there is value in perioperative surveillance looking for troponin leakage in the absence of other criteria for MI, the question remains whether early therapy could affect outcome in terms of morbidity and mortality either in the perioperative period or after discharge.
The new generation of hs cTn-assays has been shown to be superior to the standard troponin assays for early diagnosis of MI in two recently published studies.46,47
However, these studies did not assess the effect of the sensitive troponin assays on clinical management. Furthermore, it remains to be proven whether the results from a group of patients with a high pretest probability can be translated to postsurgical conditions.
Consistently performing better than traditional clinical risk scores and preoperative diagnostic tests, the natriuretic peptides clearly hold promise as a relatively cheap and noninvasive risk stratification tool, perhaps both pre- and postoperatively.48
Hs C-reactive protein has been shown to be predictive of both immediate postoperative outcome49
and significantly decreased overall survival50
in the setting of coronary artery bypass surgery.
Another interesting approach may be the simultaneous measurement of multiple biomarkers. Goei et al.
recently demonstrated that both hs C-reactive protein and NT-pro-brain natriuretic peptide have additional value in the prediction of postoperative cardiac events in vascular surgery patients to cardiac risk factors alone. The integrated use of both NT-pro-brain natriuretic peptide and hs C-reactive protein was able to improve cardiac risk stratification.51
Fellahi et al.52
assessed the multiple marker approach in cardiac surgery. Their recently published study showed that simultaneous measurement of cTnI, brain natriuretic peptide, and C-reactive protein improves the risk assessment of long-term adverse cardiac outcome after cardiac surgery.
The evidence to guide the rational use of perioperative cardiac monitoring, electrocardiograms, and troponins is limited, and further evaluation regarding the optimal strategy is required. On the basis of the current evidence, in patients without documented coronary artery disease, surveillance should be restricted to those who develop perioperative signs of cardiovascular dysfunction. In patients with high or intermediate clinical risk who have known or suspected coronary artery disease and who are undergoing high- or intermediate-risk surgical procedures, serial 12-lead electrocardiograms should be obtained at baseline, immediately after the surgical procedure and on PODs 1 and 2. Consideration should be given to the use of cardiac-specific troponins for the first 4 days after surgery.
In light of all the areas of uncertainty concerning the clinical value of measuring troponin leakage, the 2007 update of the American College of Cardiology/American Heart Association Perioperative Evaluation Guidelines limited the recommendation for postoperative troponin measurement to patients with electrocardiographic changes or chest pain typical of acute coronary syndrome (level of evidence: C).53
The European Society of Cardiology Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery that were published in August 2009 do not recommend routine biomarker sampling to prevent cardiac events.54
1.Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L: Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043–9
2.Shah KB, Kleinman BS, Rao TL, Jacobs HK, Mestan K, Schaafsma M: Angina and other risk factors in patients with cardiac diseases undergoing noncardiac operations. Anesth Analg 1990; 70:240–7
3.Landesberg G: The pathophysiology of perioperative myocardial infarction: Facts and perspectives. J Cardiothorac Vasc Anesth 2003; 17:90–100
4.Mangano DT: Adverse outcomes after surgery in the year 2001—a continuing odyssey. Anesthesiology 1998; 88:561–4
5.Mangano DT: Perioperative cardiac morbidity. Anesthesiology 1990; 72:153–84
6.Priebe HJ: Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004; 93:9–20
7.Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, Weissman C, Mosseri M: Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003; 42:1547–54
8.Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH: Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: A review. CMAJ 2005; 173:779–88
9.Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50:2173–95
10.Hurst JW: Thoughts about the abnormalities in the electrocardiogram of patients with acute myocardial infarction with emphasis on a more accurate method of interpreting S-T segment displacement: Part II. Clin Cardiol 2007; 30:443–9
11.Karmen A, Wroblewski F, Ladue JS: Transaminase activity in human blood. J Clin Invest 1955; 34:126–31
12.Dreyfus JC, Schapira G, Resnais J, Scebat L: [Serum creatine kinase in the diagnosis of myocardial infarct]. Rev Fr Etud Clin Biol 1960; 5:386–7
13.van der Veen KJ, Willebrands AF: Isoenzymes of creatine phosphokinase in tissue extracts and in normal and pathological sera. Clin Chim Acta 1966; 13:312–6
14.McGrath RB, Revtyak G: Secondary myocardial injuries. Crit Care Med 1984; 12:1024–6
15.Vaidya HC, Maynard Y, Dietzler DN, Ladenson JH: Direct measurement of creatine kinase-MB activity in serum after extraction with a monoclonal antibody specific to the MB isoenzyme. Clin Chem 1986; 32:657–63
16.Rosalki SB, Roberts R, Katus HA, Giannitsis E, Ladenson JH, Apple FS: Cardiac biomarkers for detection of myocardial infarction: Perspectives from past to present. Clin Chem 2004; 50:2205–13
17.Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R: Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999; 99:1671–7
18.Balk EM, Ioannidis JP, Salem D, Chew PW, Lau J: Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: A meta-analysis. Ann Emerg Med 2001; 37:478–94
19.Wu AH, Lane PL: Metaanalysis in clinical chemistry: Validation of cardiac troponin T as a marker for ischemic heart diseases. Clin Chem 1995; 41:1228–33
20.Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H: It's time for a change to a troponin standard. Circulation 2000; 102:1216–20
21.Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, Wu AH: Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50:327–32
22.Jaffe AS, Babuin L, Apple FS: Biomarkers in acute cardiac disease: The present and the future. J Am Coll Cardiol 2006; 48:1–11
23.Giannitsis E, Katus HA: Comparison of cardiac troponin T and troponin I assays—implications of analytical and biochemical differences on clinical performance. Clin Lab 2004; 50:521–8
24.Okmen E, Kasikcioglu H, Sanli A, Uyarel H, Cam N: Correlations between cardiac troponin I, cardiac troponin T, and creatine phosphokinase MB elevation following successful percutaneous coronary intervention and prognostic value of each marker. J Invasive Cardiol 2005; 17:63–7
25.Wu AH: A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Coron Artery Dis 1999; 10:69–74
26.Apple FS: A new season for cardiac troponin assays: It's time to keep a scorecard. Clin Chem 2009; 55:1303–6
27.Adams JE III, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Davila-Roman VG, Bodor GS, Ladenson JH, Jaffe AS: Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330:670–4
28.Lee TH, Thomas EJ, Ludwig LE, Sacks DB, Johnson PA, Donaldson MC, Cook EF, Pedan A, Kuntz KM, Goldman L: Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77:1031–6
29.Metzler H, Gries M, Rehak P, Lang T, Fruhwald S, Toller W: Perioperative myocardial cell injury: The role of troponins. Br J Anaesth 1997; 78:386–90
30.Haggart PC, Adam DJ, Ludman PF, Bradbury AW: Comparison of cardiac troponin I and creatine kinase ratios in the detection of myocardial injury after aortic surgery. Br J Surg 2001; 88:1196–200
31.Jules-Elysee K, Urban MK, Urquhart B, Milman S: Troponin I as a diagnostic marker of a perioperative myocardial infarction in the orthopedic population. J Clin Anesth 2001; 13:556–60
32.Martinez EA, Nass CM, Jermyn RM, Rosenbaum SH, Akhtar S, Chan DW, Malkus H, Weiss JL, Fleisher LA: Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction. J Cardiothorac Vasc Anesth 2005; 19:577–82
33.Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B: Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology 2005; 102:885–91
34.Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson PA, Cook EF, Lee TH: Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29:1241–5
35.Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW: Myocardial infarction after noncardiac surgery. Anesthesiology 1998; 88:572–8
36.Neill F, Sear JW, French G, Lam H, Kemp M, Hooper RJ, Foex P: Increases in serum concentrations of cardiac proteins and the prediction of early postoperative cardiovascular complications in noncardiac surgery patients. Anaesthesia 2000; 55:641–7
37.Godet G, Dumerat M, Baillard C, Ben Ayed S, Bernard MA, Bertrand M, Kieffer E, Coriat P: Cardiac troponin I is reliable with immediate but not medium-term cardiac complications after abdominal aortic repair. Acta Anaesthesiol Scand 2000; 44:592–7
38.Kim LJ, Martinez EA, Faraday N, Dorman T, Fleisher LA, Perler BA, Williams GM, Chan D, Pronovost PJ: Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106:2366–71
39.Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N: Universal definition of myocardial infarction. Circulation 2007; 116:2634–53
40.Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, Minder EI, Rickli H, Fehr T: Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41:2004–9
41.Ammann P, Fehr T, Minder EI, Gunter C, Bertel O: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27:965–9
42.Wu AH: Increased troponin in patients with sepsis and septic shock: Myocardial necrosis or reversible myocardial depression? Intensive Care Med 2001; 27:959–61
43.Guest TM, Ramanathan AV, Tuteur PG, Schechtman KB, Ladenson JH, Jaffe AS: Myocardial injury in critically ill patients. A frequently unrecognized complication JAMA 1995; 273:1945–9
44.Yalamanchili K, Sukhija R, Aronow WS, Sinha N, Fleisher AG, Lehrman SG: Prevalence of increased cardiac troponin I levels in patients with and without acute pulmonary embolism and relation of increased cardiac troponin I levels with in-hospital mortality in patients with acute pulmonary embolism. Am J Cardiol 2004; 93:263–4
45.Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E: Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: Results from TIMI 35. Eur Heart J 2009; 30:162–9
46.Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858–67
47.Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361:868–77
48.Ryding AD, Kumar S, Worthington AM, Burgess D: Prognostic value of brain natriuretic peptide in noncardiac surgery: A meta-analysis. Anesthesiology 2009; 111:311–9
49.Biancari F, Lahtinen J, Lepojarvi S, Rainio P, Salmela E, Pokela R, Lepojarvi M, Satta J, Juvonen TS: Preoperative C-reactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg 2003; 76:2007–12
50.Kangasniemi OP, Biancari F, Luukkonen J, Vuorisalo S, Satta J, Pokela R, Juvonen T: Preoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg 2006; 29:983–5
51.Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D: Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients. Coron Artery Dis 2009; 20:219–24
52.Fellahi JL, Hanouz JL, Manach YL, Gue X, Monier E, Guillou L, Riou B: Simultaneous measurement of cardiac troponin I, B-type natriuretic peptide, and C-reactive protein for the prediction of long-term cardiac outcome after cardiac surgery. Anesthesiology 2009; 111:250–7
53.Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Md RN, Ornato JP, Page RL, Tarkington LG, Yancy CW: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:1971–96
54.Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F, Hoeks SE, Vanhorebeek I, Vahanian A, Auricchio A, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, De Caterina R, Agewall S, Al Attar N, Andreotti F, Anker SD, Baron-Esquivias G, Berkenboom G, Chapoutot L, Cifkova R, Faggiano P, Gibbs S, Hansen HS, Iserin L, Israel CW, Kornowski R, Eizagaechevarria NM, Pepi M, Piepoli M, Priebe HJ, Scherer M, Stepinska J, Taggart D, Tubaro M: Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30:2769–812
© 2010 American Society of Anesthesiologists, Inc.